ZYBERNO
Stock Report
Updated Sep 1, 2026

GUIDED THERAPEUTICS, INC. (GTHP)

Healthcare • OTC

$0.23

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
GUIDED THERAPEUTICS, INC. (GTHP) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-303.8%)
Return on Capital (Capital Efficiency):CRITICAL (-124.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

GUIDED THERAPEUTICS, INC. (GTHP) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, GTHP generated -$1.75M in Owner Earnings. Reinvestment rate: 0.5%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.23
Market Cap:$21.72M

Valuation Multiples (2)

P/S Ratio:33.42x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$22.40M

Price Action & Momentum (3)

Momentum Percentile:32 / 100
% of 52-Week High:41.7%
B. Profitability Assessment

Return Metrics (4)

ROA:-277.7%
Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.7%

Margin Analysis (3)

Operating Margin Ttm:-303.8%
Net Margin Ttm:-536.9%
Ebitda Margin:-302.3%

TTM Performance (3)

Gross Margin Ttm:75.7%
Operating Margin Ttm:-303.8%
Net Margin Ttm:-536.9%

Yield Metrics (2)

Earnings Yield:-$13.79
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-700.0%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):100.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.09x
Quick Ratio:0.00x
Cash Ratio:0.00x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-3.95x
Times Interest Earned:-3.95

Capital Structure (4)

Working Capital:-5,642,000.00
Cash And Cash Equivalents:0.00
Long Term Debt:$602.00K
Net Debt:$683.00K
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $650.00K
Linear Growth: 100.0%
📊 Click to view full GTHP Revenue analysis & methodology →
Cost Of Revenue Ttm:$158.00K

Profitability Breakdown (2)

Gross profit TTM: $492.00K
Linear Growth: 100.0%
📊 Click to view full GTHP Gross Profit analysis & methodology →
-$1.98M

Bottom Line Performance (3)

-$3.49M
Income Before Tax:-$3.06M
Ebitda Ttm:-1,965,000.00

Operating Expenses (5)

Operating Expenses:2,467,000.00
R And D Expense:341,000.00
Sga Expense:2,254,000.00
Income Tax Expense:$0.00
Interest Expense:600,000.00

Expense Ratios (1)

Ebitda Margin:-302.3%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.20M
Current Assets:$527.00K
Ppe Net:1,616,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:6,958,000.00
Current Liabilities:6,169,000.00
Long Term Debt:$602.00K
Short Term Debt:$81.00K

Equity & Capital (3)

Equity:-$5.76M
Retained Earnings:-$158.67M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:4,000.00
Inventory:500,000.00
Accounts Payable:2,347,000.00

Special Items (2)

Contract Liabilities:189,000.00
Stock Based Compensation:68,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.35M-$1.75M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:0.00

Financing Activities (3)

Financing Cash Flow:$923.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$5.26M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:10,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.04
-$0.04
Earnings Per Share Ttm:-$0.04

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.01

Book Value & Capital (2)

Book Value Per Share:-$0.06
Cash Per Share:-999.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.52x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:162.50x
Days Sales Outstanding Ttm:2.25

Inventory Management (2)

Inventory Turnover Ttm:0.32x
Days Inventory Outstanding Ttm:1,155.06

Payables & Cash Cycle (2)

Days Payable Outstanding:5,421.87
Cash Conversion Cycle:-4,264.56
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:15.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$1.75M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.5%
Fundamental Growth Rate (g):-0.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):100.0%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):100.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:GTHP
Company Name:GUIDED THERAPEUTICS, INC.
Sector:Healthcare
Industry:Medical Technology
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:96.54M
Shares Outstanding Basic:96.54M
Shares Outstanding Diluted:96.54M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 12:28:49 UTC
Data Timestamp:2026-08-21T05:40:56.279780
Scroll to Top